Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/tipiracil plus Fruquintinib in 3rd-line mCRC
NCT06485713Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib and trifluridine + tipiracil in metastatic colorectal cancer (mCRC) (3 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Progression-free survival at 24 weeks. Started Mar 2024; status: recruiting.
02
Drugs
fruquintinibtrifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06485713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485713.